CorMedix Inc. (CRMD) Balance Sheet

The dramatic expansion in the asset base appears to be driven by the successful commercial launch of DefenCath and the subsequent accumulation of cash and receivables. This trajectory suggests that the company is effectively leveraging its regulatory milestones to build a more substantial financial foundation, though investors should monitor whether this growth remains sustainable as the initial market penetration phase concludes.

The introduction of debt appears to be a strategic move to fund the infrastructure required for a national commercial rollout rather than a necessity-driven measure for survival. While the current leverage remains manageable, the company's ability to service this debt will depend heavily on the continued stability of its high-margin revenue streams and the avoidance of a reimbursement cliff.

The decline in the current ratio is a natural consequence of moving from a cash-hoarding R&D phase to an active commercial phase where capital is tied up in inventory and accounts receivable. This liquidity position appears sufficient to buffer against short-term shocks, provided that the conversion of receivables into cash remains consistent with the company's historical performance.